Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-DFO-AP-101
- Development stage
- Phase 1
- Lead developer
- Eli Lilly
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
89Zr-DFO-AP-101 is a radiolabeled antibody-based diagnostic radiopharmaceutical designed for use in positron emission tomography (PET) imaging. It utilizes the radioisotope zirconium‑89 (89Zr) chelated with desferrioxamine (DFO) and conjugated to the AP‑101 antibody. The primary mechanism of action is as a PET imaging agent, enhancing visualization of specific molecular targets in vivo. Its main clinical application under investigation is for detecting misfolded SOD1 protein associated with amyotrophic lateral sclerosis (ALS), aiming to improve diagnosis and disease monitoring in ALS patients. The drug is currently being evaluated in phase 1 clinical trials for its safety, biodistribution, pharmacokinetics, and dosimetry in both healthy volunteers and ALS patients[1][5]. Eli Lilly & Co. is listed as the active organization involved in its development[1].
- Other names
- [89Zr]Zr-DFO-AP-101
02
Targets
Misfolded SOD1
Beyond the preview
Go deeper on 89Zr-DFO-AP-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-DFO-AP-101.